Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 29:ciaf033.
doi: 10.1093/cid/ciaf033. Online ahead of print.

Efficacy, immunogenicity, and safety of an investigational maternal respiratory syncytial virus prefusion F protein-based vaccine

Peyman Banooni  1 , Bernard Gonik  2 , Cristina Epalza  3 , Osvaldo Reyes  4 , Shabir A Madhi  5 , Grace Devota Gomez-Go  6 , Khalequ Zaman  7 , Conrado Juan Llapur  8 , Eduardo López-Medina  9 , Thorsten Stanley  10 , Anu Kantele  11 , Li-Min Huang  12 , Marisa Márcia Mussi-Pinhata  13 , Jonas Dewulf  14 , Joanne M Langley  15 , Claudia Seidl  16 , Martin Ota  17 , Martha Kirabo  18 , Bruno Anspach  19 , Ilse Dieussaert  18 , Ouzama Henry  19 , Joon Hyung Kim  19 , Marta Picciolato  18
Affiliations

Efficacy, immunogenicity, and safety of an investigational maternal respiratory syncytial virus prefusion F protein-based vaccine

Peyman Banooni et al. Clin Infect Dis. .

Abstract

Background: In this phase 3 trial of an investigational maternal respiratory syncytial virus prefusion F protein-based vaccine (RSVPreF3-Mat), a higher rate of preterm birth was observed in the vaccine (6.8%) versus the placebo group (4.9%). Trial enrollment and vaccination were stopped. Results of investigations into this safety signal were reported previously. Here, we describe end-of-trial efficacy, immunogenicity, and safety results.

Methods: Women 18-49 years old were randomized 2:1 to receive one dose of RSVPreF3-Mat (n=3557) or placebo (n=1771) at 240/7-340/7 weeks' gestation. Primary outcomes were any and severe medically assessed RSV-associated lower respiratory tract disease (MA-RSV-LRTD) in infants until 6 months post-birth and safety until 12 months post-birth. Other efficacy outcomes were evaluated, along with immunogenicity (until 6 months post-partum/birth) and safety in mothers and infants.

Results: Efficacy in infants until 6 months post-birth was 65.5% (95% credible interval: 37.5-82.0) against any MA-RSV-LRTD, 69.0% (33.0-87.6) against severe MA-RSV-LRTD, and 50.1% (-3.6-75.8) against RSV hospitalization; it waned over time thereafter. Efficacy against MA-RSV-LRTD was 47.8% (-25.8-77.3) in low- and middle-income and 75.9% (46.1-91.5) in high-income countries. RSVPreF3-Mat induced a substantial increase in RSV-A neutralization titers in mothers, with efficient transplacental transfer of antibodies that persisted in infants until at least 6 months post-birth.

Conclusion: Consistent with the high titers of transplacentally transferred antibodies, this trial suggests a reduced risk of any/severe MA-RSV-LRTD and RSV hospitalization until 6 months post-birth in infants born to mothers immunized with RSVPreF3-Mat during pregnancy. However, vaccine development was terminated due to an identified preterm birth risk.

Trial registration: ClinicalTrials.gov: NCT04605159.

Keywords: efficacy; maternal immunization; prefusion F protein; preterm birth; respiratory syncytial virus; safety; transplacental transfer.

PubMed Disclaimer

Associated data